收费全文 | 24610篇 |
免费 | 1957篇 |
国内免费 | 42篇 |
耳鼻咽喉 | 276篇 |
儿科学 | 874篇 |
妇产科学 | 575篇 |
基础医学 | 3324篇 |
口腔科学 | 691篇 |
临床医学 | 2955篇 |
内科学 | 4258篇 |
皮肤病学 | 357篇 |
神经病学 | 2281篇 |
特种医学 | 795篇 |
外国民族医学 | 1篇 |
外科学 | 3937篇 |
综合类 | 486篇 |
一般理论 | 13篇 |
预防医学 | 2385篇 |
眼科学 | 611篇 |
药学 | 1348篇 |
中国医学 | 6篇 |
肿瘤学 | 1436篇 |
2022年 | 168篇 |
2021年 | 367篇 |
2020年 | 225篇 |
2019年 | 372篇 |
2018年 | 493篇 |
2017年 | 342篇 |
2016年 | 322篇 |
2015年 | 400篇 |
2014年 | 662篇 |
2013年 | 920篇 |
2012年 | 1295篇 |
2011年 | 1354篇 |
2010年 | 789篇 |
2009年 | 674篇 |
2008年 | 1154篇 |
2007年 | 1263篇 |
2006年 | 1225篇 |
2005年 | 1284篇 |
2004年 | 1178篇 |
2003年 | 1102篇 |
2002年 | 1013篇 |
2001年 | 562篇 |
2000年 | 565篇 |
1999年 | 518篇 |
1998年 | 296篇 |
1997年 | 217篇 |
1996年 | 225篇 |
1995年 | 195篇 |
1994年 | 209篇 |
1993年 | 192篇 |
1992年 | 473篇 |
1991年 | 400篇 |
1990年 | 373篇 |
1989年 | 362篇 |
1988年 | 356篇 |
1987年 | 315篇 |
1986年 | 333篇 |
1985年 | 327篇 |
1984年 | 254篇 |
1983年 | 263篇 |
1982年 | 195篇 |
1981年 | 209篇 |
1980年 | 183篇 |
1979年 | 278篇 |
1978年 | 213篇 |
1977年 | 172篇 |
1975年 | 162篇 |
1974年 | 199篇 |
1973年 | 211篇 |
1972年 | 163篇 |
Background
In a pooled analysis of the phase 3 Controlled Myelofibrosis Study With Oral JAK Inhibitor Treatment I (COMFORT-I) and COMFORT-II clinical trials, adult patients with intermediate-2 or high-risk myelofibrosis who received oral ruxolitinib at randomization or after crossover from placebo or best available therapy (BAT) had improved overall survival (OS).Methods
This post hoc analysis of pooled COMFORT data examined relevant disease outcomes based on the disease duration (≤12 or >12 months from diagnosis) before ruxolitinib initiation.Results
The analysis included 525 patients (ruxolitinib: ≤12 months, n = 84; >12 months, n = 216; placebo/BAT: ≤12 months, n = 66; >12 months, n = 159); the median age was 65.0–70.0 years. Fewer thrombocytopenia and anemia events were observed among patients who initiated ruxolitinib treatment earlier. At Weeks 24 and 48, the spleen volume response (SVR) was higher for patients who initiated ruxolitinib earlier (47.6% vs. 32.9% at Week 24, p = .0610; 44.0% vs. 26.9% at Week 48, p = .0149). In a multivariable analysis of factors associated with spleen volume reduction, a logistic regression model that controlled for confounding factors found that a significantly greater binary reduction was observed among patients with shorter versus longer disease duration (p = .022). At Week 240, OS was significantly improved among patients who initiated ruxolitinib earlier (63% [95% CI, 51%‒73%] vs. 57% [95% CI, 49%‒64%]; hazard ratio, 1.53; 95% CI, 1.01‒2.31; p = .0430). Regardless of disease duration, a longer OS was observed for patients who received ruxolitinib versus those who received placebo/BAT.Conclusions
These findings suggest that earlier ruxolitinib initiation for adult patients with intermediate-2 and high-risk myelofibrosis may improve clinical outcomes, including fewer cytopenia events, durable SVR, and prolonged OS.Plain Language Summary
- Patients with myelofibrosis, a bone marrow cancer, often do not live as long as the general population. These patients may also have an enlarged spleen and difficult symptoms such as fatigue.
- Two large clinical trials showed that patients treated with the drug ruxolitinib lived longer and had improved symptoms compared to those treated with placebo or other standard treatments.
- Here it was examined whether starting treatment with ruxolitinib earlier (i.e., within a year of diagnosis) provided benefits versus delaying treatment.
- Patients who received ruxolitinib within a year of diagnosis lived longer and experienced fewer disease symptoms than those whose treatment was delayed.
Methods: A retrospective analysis was performed to identify patients with isolated PCL injuries that underwent reconstruction between 2001 and 2014. Patients with multi-ligamentous injury or another concomitant knee pathology were excluded. Medical records were reviewed for demographic, clinical and operative data. Patients were contacted for administration of a telephone-based questionnaire which included the International Knee Documentation Committee (IKDC) Subjective Knee Evaluation form, Lysholm-Tegner scales, Marx activity scale (MAS), return to sport status, and patient satisfaction instruments.
Results: A total of 15 isolated PCL reconstructions in 14 patients with a mean age of 27.5 years (range 17–43) met the study inclusion criteria; mean follow up was 6.3 years (range 1.4–15.2). Pre-operatively, the primary complaint was knee instability in all patients; on physical examination, lack of a firm end point during posterior drawer testing was found in 93% (14/15) of the knees. In total, 12 of 15 knees underwent transtibial, single-bundle PCLR and three of 15 underwent tibial inlay, double bundle PCLR. Graft types included: quadriceps autograft (7/15), Achilles allograft (6/15), and hamstring autograft (2/15). There were no graft failures in our patient cohort. At most recent follow up the mean scores respectively on the IKDC form, Lysholm-Tegner scales and MAS were (standard deviation): 77.3 (16.5), 83.1 (17.9), 6.13 (2.6), and 7.1 (6.0). All fourteen patients were athletes prior to their injury and 79% (11/14) returned to sport and overall patient satisfaction was 9.2/10.
Conclusions: Isolated PCLR provides good outcomes at mean medium-term follow up with restoration of function, high rate of return to sport and overall patient satisfaction. 相似文献
![点击此处可从《Clinical and experimental allergy》网站下载免费的PDF全文](/ch/ext_images/free.gif)